Catalog No.
YHH24701
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Lys180-Lys274
Predicted molecular weight
23.76 kDa
Nature
Recombinant
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q16204
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
D10S170, Coiled-coil domain-containing protein 6, Papillary thyroid carcinoma-encoded protein, TST1, Protein H4, CCDC6
Note
For research use only.
An integrative pan cancer analysis of RET aberrations and their potential clinical implications., PMID:35978072
RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer., PMID:36059009
Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells., PMID:36126466
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study., PMID:36129569
High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma., PMID:36186907
FGFR2-CCDC6 fusion gene promotes the proliferation of Hucct-1 cells., PMID:36227665
1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions., PMID:36308779
Reversing "Flip-Flop" Phenomenon of 131 I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib., PMID:36327463
Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report., PMID:36451418
Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib., PMID:36657661
Function of TRPC1 in modulating hepatocellular carcinoma progression., PMID:36797544
Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors., PMID:36905915
Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases., PMID:36977550
Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer., PMID:36995892
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers., PMID:36996322
Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer., PMID:37081420
Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation., PMID:37141396
RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients., PMID:37188126
Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial., PMID:37315261
Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma., PMID:37469257
Sweat Gland Tumors Arising on Acral Sites: A Molecular Survey., PMID:37505808
Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification., PMID:37744220
Competitive binding of circCCDC6 to microRNA-128-3p activates TXNIP/NLRP3 pathway and promotes cerebral ischemia-reperfusion defects., PMID:37934513
Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer., PMID:38140788
TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort., PMID:38170436
Identification of potential prognostic biomarkers among gene models for coiled-coil domain-containing family members in hepatocellular carcinoma elucidates their influence on the hypoxia pathway and immune microenvironment., PMID:38196528
Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer., PMID:38198957
Long Non-coding RNA 02298 Promotes the Malignancy of HCC by Targeting the miR-28-5p/CCDC6 Pathway., PMID:38381357
[Stratified application of gene expression in diagnosis of thyroid nodules]., PMID:38433054
Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability., PMID:38580884
Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition., PMID:38696710
Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC., PMID:38768929
CCDC6-RET fusion protein regulates Ras/MAPK signaling through the fusion- GRB2-SHC1 signal niche., PMID:38805286
Multifocal Papillary Thyroid Carcinomas With Discordant Molecular Drivers: Emphasizing the Morphology and Collision Tumors., PMID:38818543
Targeted sequencing of DNA/RNA combined with radiomics predicts lymph node metastasis of papillary thyroid carcinoma., PMID:38886866
Hidrocystoma-like tumours with RET or ALK fusion: a study of four cases., PMID:39009490
A post-irradiation-induced replication stress promotes RET proto-oncogene breakage., PMID:39047147
Low-dose ionizing radiation-induced RET/PTC1 rearrangement via the non-homologous end joining pathway to drive thyroid cancer., PMID:39135916
Clinicopathological Features of CCDC6-RET and NCOA4-RET Fusions in Thyroid Cancer: A Single-Center Retrospective Cohort Study in a Chinese Population., PMID:39212716
Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China., PMID:39316291
Descriptive Analysis of Common Fusion Mutations in Papillary Thyroid Carcinoma in Hungary., PMID:39409115
Functional Targets for Epstein-Barr Virus BART MicroRNAs in B Cell Lymphomas., PMID:39456631
Structure-Based Design of 2-Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection (RET) Kinase Inhibitors., PMID:39739433
[Characteristics of RET gene rearrangement detected by fluorescence in situ hybridization in lung cancer]., PMID:39762169
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs., PMID:39800214
Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer., PMID:39833990
Design, synthesis and evaluation of (E)-1-(4-(2-(1H-pyrazol-5-yl)vinyl)phenyl) derivatives as next generation selective RET inhibitors overcoming RET solvent front mutations (G810C/R)., PMID:39879936
Clinical, Morphologic, and Genomic Findings in Spitz Tumors With RET Fusion: A Series of 31 Cases., PMID:39986469
Primary low-grade salivary gland-type intraductal carcinoma of the lung with CCDC6::RET fusion: Case presentation and literature review., PMID:40036626
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy., PMID:40496186
For research use only. Not for human or drug use.
